Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AccurayARAY -5.66%44 EV-to-EBIT is -11.23 as of Jul. 27, 2026. GuruFocus rates ARAY with a GF Score™ of 44/100 and a GF Value™ of $1.34 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Accuray ranks worse than 214592.06% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Accuray's Enterprise Value is $171.1 Mil.
Accuray's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-15.2 Mil. Therefore, Accuray's EV-to-EBIT for today is -11.23.
The historical rank and industry rank for Accuray's EV-to-EBIT or its related term are showing as below:
ARAY'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1888.78 Med: 14.52 Max: 599.71
Current: -11.23
During the past 13 years, the highest EV-to-EBIT of Accuray was 599.71. The lowest was -1888.78. And the median was 14.52.
ARAY's EV-to-EBIT is ranked worse than 100% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.395
vs ARAY: -11.23
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Accuray's Enterprise Value for the quarter that ended in Mar. 2026 was $190.5 Mil.
Accuray's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accuray EV-to-EBIT Related Terms
Accuray EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Accuray's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Accuray's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accuray EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accuray's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Accuray's EV-to-EBIT falls into.
Accuray's current Enterprise Value is $171.1 Mil.
Accuray's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accuray (ARAY) has a EV-to-EBIT of -11.23 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Accuray and its competitors. According to the industry distribution chart, Accuray ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Accuray's EV-to-EBIT too high?
Accuray's current EV-to-EBIT is -11.23. Based on the distribution chart, Accuray ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Accuray has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Accuray's EV-to-EBIT compare to RDGL and FOFA?
According to the Medical Devices & Instruments industry distribution chart, Accuray ranks #999999 out of 466 companies for EV-to-EBIT. This places Accuray in the lower half of its industry. The industry median EV-to-EBIT is 18.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Accuray and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accuray's current EV-to-EBIT is -11.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accuray stock overvalued right now?
Based on GuruFocus' analysis, Accuray (ARAY) is currently considered Possible Value Trap. The stock's GF Value™ is $1.34, compared to a current price of $0.23 — trading 83.1% below its estimated fair value. The current EV-to-EBIT is -11.23. Accuray's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Accuray (ARAY), the current EV-to-EBIT is -11.23 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Accuray (ARAY) Overvalued in 2026?
Based on GuruFocus' analysis, Accuray stock appears to be undervalued.
The current stock price of $0.23 is trading 83.1% below its estimated GF Value™ of $1.34.
GuruFocus considers Accuray to be Possible Value Trap.
Key valuation signals for ARAY:
EV-to-EBIT: -11.23
GF Value™: $1.34 vs. price of $0.23 (83.1% below fair value)
No single metric tells the full story. See the ARAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
44GF Score
Get the complete analysis for ARAY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARAY has been successfully added to your 
